Summary:
- Eli Lilly's (LLY, Financial) shares jumped over 13% due to impressive Phase 3 trial results for their diabetes drug, orforglipron.
- Analysts predict an average price target of $1,012.05, indicating a potential upside of 20.49%.
- GuruFocus' estimated GF Value for LLY is $1,126.67, suggesting a 34.13% upside.
Eli Lilly (LLY) has captured investor attention with a significant 13% surge in share value, following the announcement of promising results from its oral diabetes medication, orforglipron. The Phase 3 trial revealed that orforglipron effectively reduced A1C levels and supported weight loss in patients with type 2 diabetes, highlighting its competitive edge in the pharmaceutical industry.
Wall Street Analysts Forecast
Wall Street analysts are optimistic about Eli Lilly's prospects. According to projections from 25 analysts, the average one-year price target for Eli Lilly and Co (LLY, Financial) stands at $1,012.05, with a high of $1,190.00 and a low of $800.00. This average target signifies a potential upside of 20.49% from the present stock price of $839.96. To explore more detailed forecast data, visit the Eli Lilly and Co (LLY) Forecast page.
The consensus recommendation from 29 brokerage firms positions Eli Lilly and Co (LLY, Financial) with an average brokerage recommendation of 1.9, indicating an "Outperform" status. On the rating scale where 1 indicates Strong Buy and 5 represents Sell, Eli Lilly's standing reflects confidence from market analysts.
GF Value Insight
According to GuruFocus estimates, the projected GF Value for Eli Lilly and Co (LLY, Financial) in the coming year is $1,126.67. This estimate suggests a notable upside of 34.13% from the current market price of $839.96. The GF Value metric is GuruFocus' assessment of the stock's fair trading value, derived from historical trading multiples, past business growth, and future performance forecasts. For more comprehensive insights, visit the Eli Lilly and Co (LLY) Summary page.
